Financial Performance - The company reported a profit attributable to shareholders of $2,922 thousand for the six months ended June 30, 2023, compared to a loss of $73,051 thousand in the same period of 2022[3]. - The basic and diluted earnings per share for the period were both $0.00, an improvement from a loss of $0.10 per share in the prior year[3]. - The company reported a total revenue of $727.36 million for the first half of 2023, representing a significant increase compared to the previous period[73]. - Revenue for the six months ended June 30, 2023, was $40.996 million, a 48.1% increase from $27.630 million in the same period of 2022[126]. - The company reported a profit of $2.914 million for the period, compared to a loss of $73.079 million in the previous year[126]. - Cash and bank balances increased to $179.339 million from $171.705 million, indicating a strong liquidity position[126]. - The total assets decreased slightly to $223.513 million from $232.123 million, while total liabilities also decreased to $123.152 million from $139.622 million[126]. Shareholder and Equity Information - The company did not repurchase any of its own ordinary shares during the reporting period, compared to the repurchase of 1,468,000 shares for a total cost of approximately $753,000 in the prior year[26]. - The number of restricted share units at the end of the reporting period was 7,671,904, an increase from 4,149,840 in the same period of 2022[25]. - The company issued 39,967,000 stock options during the six months ended June 30, 2023, resulting in a total of 35,678,050 stock options outstanding at the end of the period[34]. - The company had a weighted average number of ordinary shares issued of 732,387,673 for the period, slightly down from 732,901,025 in the previous year[3]. - The company confirmed share-based payment expenses of $775,000 for the first half of 2023 under the 2016 equity incentive plan, a decrease from $5,717,000 for the same period in 2022[69]. - Share-based payment expenses related to the post-IPO stock option plan amounted to $1,492,000 for the first half of 2023, with no expenses recorded for the same period in 2022[70]. - The share-based payment expenses significantly decreased to $848,000 from $4,248,000, representing a decline of 80%[90]. - The total management compensation for the first half of 2023 was $2,949,000, down 54.5% from $6,488,000 in the same period of 2022[90]. Trade Receivables and Credit Quality - Trade receivables aged less than three months at the end of the reporting period were $16,398 thousand, a decrease from $22,029 thousand as of December 31, 2022[10]. - Trade receivables as of June 30, 2023, amounted to $7,191,000, slightly up from $7,118,000 as of December 31, 2022, indicating a growth of 1.0%[40]. - The company reported minimal expected credit losses on trade receivables, indicating strong credit quality[7]. - The company’s trade receivables are fully impaired, with no provisions for bad debts reported[40]. - The company has an outstanding receivable from associates amounting to $2.768 million as of June 30, 2023, slightly down from $2.872 million in the previous year[89]. Research and Development - The company has a diverse product pipeline with over ten potential differentiated drug candidates, four of which are in clinical development[106]. - The company’s management highlighted ongoing research and development efforts aimed at enhancing product offerings and technological advancements[83]. - The company is focused on expanding its innovative pipeline, particularly in the field of tumor immunotherapy and autoimmune diseases[120][121]. - The company aims to maximize the value of its platforms by focusing on innovative and efficient industry partnerships[111]. - The company is exploring multiple projects in tumor immunity and autoimmune diseases, including novel monoclonal antibody projects[109]. - The company has observed significant market opportunities despite challenges in global drug development and commercialization due to policy changes[188]. Clinical Trials and Product Development - HBM4003, a next-generation fully human anti-CTLA-4 antibody, is the first fully human heavy-chain antibody to enter clinical development globally, showing improved pharmacokinetic characteristics compared to traditional anti-CTLA-4 antibodies[107]. - The company completed a Phase III clinical trial for generalized myasthenia gravis (gMG) in March 2023[114]. - The company submitted a Biologics License Application (BLA) for the treatment of gMG, which was accepted by the National Medical Products Administration (NMPA) in June 2023[149]. - HBM4003, a next-generation fully human anti-CTLA-4 antibody, is in global development for various solid tumors, with significant progress reported in ongoing trials[145]. - The company has initiated Phase I trials for HBM1020 and HBM1022, with FDA IND approvals received in January and February 2023 respectively[128][129]. - A global licensing agreement was established with AstraZeneca for HBM7022, which has also received FDA IND approval and commenced Phase I trials[132]. - The company completed the first patient dosing in a Phase I trial for HBM1020 in June 2023[152]. - HBM1007 received IND approval from the FDA in January 2023, initiating a Phase I trial for solid tumors[153]. - The company is advancing collaborations with Boston Children's Hospital to identify and develop new antibody therapies, completing seed financing for HBM Alpha Therapeutics in January 2023[160]. Strategic Collaborations and Partnerships - Strategic collaborations were formed with Mythic Therapeutics and PIRC to enhance the development of ADC therapies and proprietary antibody platforms[134][135]. - The Harbour Mice® platform enables the development of fully human monoclonal antibodies, enhancing the company's innovation and sustainable growth[110]. - The company has global rights to use and develop the Harbour antibody platform, focusing on unmet medical needs and expanding collaborations with leading academic institutions[111]. - The company is exploring the integration of AI technology with its Harbour Mice® platform through a partnership with BaiTu Bio[157]. Compliance and Regulatory Matters - The company is focused on maintaining compliance with international financial reporting standards and local regulations[82]. - The revised Drug Registration Management Measures in China, effective July 2020, aim to accelerate the approval of urgently needed drugs, benefiting more patients[143].

Financial Performance - For the six months ended June 30, 2023, the company reported revenue of $40,996 thousand, a 48% increase from $27,630 thousand in the same period of 2022[27]. - The company recorded a net profit of $2,914 thousand for the period, compared to a net loss of $73,079 thousand in the previous year[27]. - Total revenue increased significantly from $27.6 million for the six months ended June 30, 2022, to $41.0 million for the six months ended June 30, 2023, primarily due to an increase in revenue from molecular licensing fees[159]. - The company reported a profit of $2.9 million for the six months ended June 30, 2023, compared to a loss of $73.1 million for the same period in 2022[165]. Cash and Assets - Cash and cash equivalents as of June 30, 2023, totaled $179,339 thousand, up from $171,705 thousand as of June 30, 2022[27]. - Total assets amounted to $223,513 thousand, a decrease from $268,307 thousand in the previous year[27]. - The company has a bank loan of USD 80.9 million and lease liabilities of USD 2.1 million as of June 30, 2023[193]. - The current ratio improved to 3.14 as of June 30, 2023, compared to 2.79 at the end of 2022, indicating better short-term financial health[144]. Research and Development - Research and development costs for the period were $28,378 thousand, compared to $83,619 thousand in the same period of 2022[27]. - R&D expenses decreased to $28.4 million for the six months ended June 30, 2023, down from $83.6 million for the same period in 2022[159]. - The company has established a strong antibody discovery platform and is focusing on innovative therapies for tumors and immune diseases, with ongoing clinical development progress[152][156]. - The company aims to submit at least one IND application annually generated from its discovery engine[48]. Collaborations and Agreements - In February 2023, the company signed a licensing and collaboration agreement with Cullinan Oncology Inc., receiving a $25 million upfront payment and potential milestone payments of up to approximately $600 million, along with high double-digit percentage royalties[31]. - The company has established a global licensing agreement with AstraZeneca for HBM7022, a new bispecific antibody, which has received IND approvals from the FDA and NMPA and has initiated global Phase I trials[31]. - The company is collaborating with Sichuan Kelong Biotechnology Co., Ltd. on HBM9378, which has entered the clinical development stage[45]. - The company established a collaboration with Boston Children's Hospital to develop innovative antibody therapies, with the main candidate HBM9013 entering the CMC development phase[88]. Clinical Trials and Product Development - The company announced positive Phase III clinical trial results for Bartolizumab (HBM9161) in treating gMG, marking its first successful Phase III trial and BLA acceptance by NMPA[63]. - HBM4003, a next-generation fully human anti-CTLA-4 antibody, is the first of its kind to enter clinical development globally, with ongoing trials showing promising efficacy and safety data[63]. - HBM1007, a fully human monoclonal antibody targeting CD73, is designed to inhibit both membrane-bound and soluble CD73, enhancing its activity in the tumor microenvironment[50]. - The company is exploring joint ventures focused on developing next-generation cell therapies to extend the application of its technology platform[129]. Financial Management and Governance - The board does not recommend the payment of an interim dividend for the six months ended June 30, 2023[175]. - The company remains committed to high standards of corporate governance to protect shareholder interests[196]. - The company has not planned any significant investments or capital asset acquisitions in the near future[191]. - The company did not engage in any significant acquisitions or disposals of subsidiaries or joint ventures during the reporting period[169]. Market and Strategic Outlook - The market demand for differentiated innovative drugs remains strong, driven by healthcare upgrades and an aging population[62]. - Harbour Therapeutics is committed to advancing its product pipeline based on clinical value and strategic partnerships[62]. - The company plans to accelerate its product pipeline in 2023, with at least one new product expected to file for IND approval through its Harbour Mice® and HBICE® discovery engines[99]. - The company anticipates broader global collaborations in 2023 as its preclinical products mature[132].

Licensing Agreements and Collaborations - The company entered a global licensing agreement with Enbipharma for HBM9161, receiving an upfront payment of RMB 150 million and potential milestone payments up to RMB 1.01 billion, along with tiered royalties based on sales[10]. - A global licensing agreement with AstraZeneca for HBM7022 includes an upfront payment of USD 25 million and potential milestone payments up to USD 325 million, plus tiered royalties based on sales[27]. - Nona Biosciences entered a collaboration with Moderna for developing nucleic acid immunotherapies, with an upfront payment of USD 6 million and potential milestone payments up to USD 500 million[12]. - Harbour Therapeutics has licensed global rights for HBM7022 to AstraZeneca and US rights for HBM7008 to Cullinan within one year[42]. - The collaboration with Nona Biosciences aims to empower industry innovators from idea to IND, showcasing a flexible business model and successful international partnerships[33]. - The collaboration with Mythic Therapeutics focuses on developing next-generation antibody-drug conjugates for various cancers[117]. - The company has entered into collaborations for ADC projects with Nona Biosciences, which will involve upfront payments, milestone payments, and royalties based on sales[143]. Clinical Development and Pipeline - HBM1020, HBM1022, and HBM1007 received IND approval from the US FDA for clinical trials in the first quarter of 2023[30]. - The company reported positive results from the pivotal Phase III clinical trial of HBM9161 for treating generalized myasthenia gravis, achieving primary and key secondary endpoints[10]. - HBM7015 has received IND approval from NMPA to initiate Phase I trials in China, with two additional projects expected to receive approval in 2023[43]. - The ongoing Phase III trial of HBM9036 (Tanezumab) for treating dry eye syndrome was halted due to insufficient efficacy trends, following recommendations from the independent data monitoring committee[47]. - The product pipeline includes candidates for melanoma, hepatocellular carcinoma, renal cell carcinoma, and other advanced solid tumors[39]. - The company has multiple products in various stages of clinical development, including Batoclimab (Phase 3 completed) and HBM9161 (Phase 2/3) targeting severe myasthenia gravis and thyroid-associated ophthalmopathy respectively[59]. - HBM9033, an antibody-drug conjugate targeting MSLN, is expected to demonstrate best-in-class therapeutic potential in its upcoming Phase 1 clinical trials[79]. - HBM4003 showed good safety in a trial for advanced melanoma, with 87.5% of patients reporting treatment-related adverse events[94]. - The company aims to submit at least one new drug IND application annually from its discovery platform[102]. Financial Performance and Position - Cash and bank balances exceeded financial liabilities as of December 31, 2022, indicating a strong liquidity position[129]. - Revenue from materials and third-party contract costs increased from $61.9 million in 2021 to $98.8 million in 2022 due to investments in key clinical projects[125]. - As of December 31, 2022, total employee costs were $14.77 million, accounting for 54.1% of total expenses, compared to $28.05 million (70.0%) in 2021[126]. - The company recorded an unrealized gain of $1.04 million from its investment in Enkasei during the reporting period, with the fair value of the investment as of December 31, 2022, being $6.36 million, representing 2.74% of the company's total assets[147]. - The current ratio as of December 31, 2022, was 2.79, down from 5.87 as of December 31, 2021[158]. - The company reported a total lease liability of $2.737 million as of December 31, 2022, down from $7.420 million the previous year[177]. - Unsecured bank borrowings amounted to $93.060 million as of December 31, 2022, compared to $11.276 million in the previous year[177]. Research and Development Focus - The company is focusing on developing highly differentiated products with clear clinical value to meet clinical needs, optimizing strategies in research, development, registration, and patents[61]. - The company is actively pursuing new product development and technological advancements in oncology, as evidenced by Dr. Rong's previous leadership in tumor projects at Roche[170]. - The company is focusing on innovative therapies for tumors and immunity, with ongoing drug discovery and preclinical research for new candidate drugs[139]. - The company has established a flexible business model around its proprietary technology platform, aiming to maximize platform value through collaboration with business partners[142]. - The company aims to leverage its expertise in capital markets to drive growth and investment opportunities[194]. Governance and Management - The company has appointed several independent directors with extensive experience in the pharmaceutical and biotechnology sectors, enhancing its governance structure[173][171]. - The company has established a strong board of directors with diverse backgrounds, including finance and biotechnology, to guide its strategic direction[189][185]. - The company has a strong management team with extensive experience in the biotechnology and financial sectors[194]. - The company has appointed a new Chief Medical Officer to strengthen its clinical development efforts[195]. - The management emphasizes the importance of innovation and believes the company will continue to grow in a rapidly developing industry, providing sustainable value to patients, employees, and shareholders[55]. Strategic Initiatives and Market Expansion - The company is exploring potential mergers and acquisitions to enhance its product pipeline and market presence[170]. - The company is strategically reallocating financial and other resources to maximize platform value and focus on core competencies, investing in projects with growth potential for more stable revenue[146]. - The company is actively pursuing market expansion strategies to increase its footprint in the biotechnology sector[199]. - The company has a commitment to maintaining high professional standards in its operations and governance[193]. - The company believes that co-development and external collaborations will enhance pipeline efficiency, reduce costs and risks, and stabilize its development[52].

Strategic Collaborations and Partnerships - The company has advanced strategic cooperation with Hualan Gene Engineering Co., Ltd. to submit IND applications for three innovative monoclonal and bispecific antibody projects between 2022 and 2023[2]. - The collaboration with AstraZeneca for the development and commercialization of HBM7022 includes a non-refundable upfront payment of $25 million and potential milestone payments up to $325 million[13]. - The company received a $6 million upfront payment and up to $500 million in milestone payments from Moderna for the licensing and collaboration agreement on nucleic acid immunotherapy[4]. - The company has established partnerships with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. for antibody-drug conjugate projects, with two products licensed to partners[3]. - The company signed a licensing and collaboration agreement with Cullinan Oncology Inc. in February 2023, granting Cullinan exclusive rights to develop and commercialize product HBM7008 in the U.S., with an upfront payment of $25 million and potential milestone payments up to $600 million, along with tiered royalties in the double-digit percentage range[27]. - The company advanced its collaboration with Boston Children's Hospital, utilizing its antibody design platform to identify new therapeutic antibodies, and completed seed financing for the joint venture HBM Alpha Therapeutics in January 2023[30]. - The company is collaborating with Nona Biosciences and Mythic Therapeutics to develop next-generation antibody-drug conjugates and other therapies[64][65]. Clinical Development and Trials - HBM4003 (Porustobart) has shown promising efficacy in treating advanced hepatocellular carcinoma (HCC) with clinical benefits observed in patients previously treated with TKIs and anti-PD-1 antibodies[24]. - The company completed patient recruitment for the Ib/II clinical trial of HBM4003 in March 2022 and presented data at ASCO 2022[20][19]. - HBM4003, a next-generation fully human heavy-chain anti-CTLA-4 antibody, is in global development for various solid tumor indications, with promising efficacy and safety observed in early trials[42][45]. - The Phase I trial of HBM4003 included a dose escalation phase and a dose expansion phase, showing an overall response rate (ORR) of 11.8% and a disease control rate (DCR) of 35.3% in previously treated patients[44]. - The company has made significant progress in the development of HBM7008, with the first patient dosed in Australia in May 2022 and approvals obtained from NMPA and FDA for Phase I clinical trials[6]. - The company decided to close the Phase III trial of HBM9036 (Tenacip) for dry eye disease due to insufficient efficacy trends observed in the interim analysis[18]. - HBM1020 received IND approval from the FDA in January 2023, initiating Phase I clinical trials in the United States[62]. Financial Performance and Revenue - The company reported a significant revenue increase to $40.7 million for the year ended December 31, 2022, up from $4.3 million in the previous year, representing a growth of 843.8%[72]. - Revenue for 2022 reached $40,659 thousand, a significant increase from $4,308 thousand in 2021, representing a growth of approximately 844%[144]. - The company reported a substantial increase in licensing fees, which amounted to $38,437 thousand in 2022 compared to $2,347 thousand in 2021, reflecting a growth of about 1535%[144]. - Revenue growth was primarily driven by licensing agreements with AstraZeneca, Enbiop Pharmaceuticals, and Moderna, with technology licensing fees remaining stable at $1.4 million for 2022 compared to $2.0 million in 2021[91]. Expenses and Losses - Research and development expenses rose to $135.1 million for the year ended December 31, 2022, compared to $107.1 million in the previous year, an increase of 26.1%[72]. - Total expenses for 2022 amounted to $135.1 million, with third-party contract costs constituting 64.3% of total expenses, up from 48.5% in 2021[93]. - The company recorded a loss of $137.3 million for the year ended December 31, 2022, slightly improved from a loss of $137.9 million in the previous year[76]. - The company reported a pre-tax loss of $137,020 thousand in 2022, slightly improved from a loss of $137,829 thousand in 2021[132]. - The company reported a pre-tax loss of $137,222 thousand in 2022, compared to a loss of $137,777 thousand in 2021, indicating a slight improvement[177]. Asset and Liability Management - Total non-current assets decreased from $41,494 thousand in 2021 to $23,111 thousand in 2022, a decline of approximately 44.5%[109]. - Current assets also decreased from $240,867 thousand in 2021 to $209,012 thousand in 2022, a reduction of about 13.2%[109]. - The total liabilities increased significantly from $59,447 thousand in 2021 to $139,622 thousand in 2022, an increase of about 134%[134]. - The company’s total equity decreased from $222,914 thousand in 2021 to $92,501 thousand in 2022, a decline of about 58.5%[135]. - The company had current assets of $28,482 thousand in 2022, an increase from $24,537 thousand in 2021, showing improved liquidity[180]. - The company’s trade receivables aging at the end of the reporting period indicated that amounts less than three months were negligible in expected credit losses[162]. - The company’s total assets as of December 31, 2022, were reported at $40,659 thousand, a significant increase from $4,308 thousand in the previous year[144]. Research and Development Focus - The company is focusing on developing highly differentiated products with clear clinical value to meet clinical needs, optimizing strategies in research, development, registration, and patenting[35]. - The company has 10 drug candidates focused on oncology and immune diseases, ranging from preclinical to late-stage clinical development[34]. - The company is actively exploring commercialization pathways for HBM9161, having licensed its rights in Greater China to CSPC Pharmaceutical Group in October 2022[66]. - The company is incubating several joint ventures focused on developing next-generation cell therapies to enhance the application of its technology platform[69]. Regulatory and Compliance - A comprehensive disease prevention plan was implemented to protect employees from COVID-19 in office and research facilities[88]. - The company’s financial statements for the year ended December 31, 2022, have been approved by its auditor, Ernst & Young[104]. - The annual general meeting is scheduled for June 8, 2023, with notifications to be issued as per listing rules[100]. Market and Investment Strategy - The company aims to maximize platform value through global partnerships and expects broader collaborations in 2023[71]. - The company has no current plans for significant investments, acquisitions, or disposals exceeding 5% of total assets[98]. - The company holds an 11.90% stake in Enkai Cell Technology after a significant investment, enhancing its technology platform strategy[86].

Product Pipeline and Development - Harbour Biomed reported a diverse product pipeline with over ten differentiated candidates, four of which are in clinical development[12]. - The company has developed HBM9161, a fully human monoclonal antibody targeting FcRn, which has potential as a breakthrough therapy for autoimmune diseases in Greater China[13]. - HBM9036, a candidate for treating moderate to severe dry eye disease, is currently in Phase III clinical trials and aims to capture a significant market share in China's rapidly growing dry eye medication market[14]. - HBM4003, a next-generation fully human anti-CTLA-4 antibody, has advanced from candidate screening to clinical development within three years, showing improved pharmacokinetics and potential for enhanced anti-tumor efficacy[15]. - HBM7008, a bispecific antibody, received approvals for Phase I clinical trials in both Australia and the U.S. in June 2022[35]. - HBM9378 received approval from the NMPA for clinical research targeting moderate to severe asthma in February 2022[37]. - The company has 12 drug candidates focused on oncology and immunology, ranging from preclinical to late-stage clinical development[44]. - HBM7008 completed Phase I clinical trials in Australia in May 2022 and received IND approval in the US and China in June 2022[44]. - HBM1020, a fully human monoclonal antibody targeting B7H7, is planned for IND submission in the second half of 2022[86]. - HBM1022, targeting CCR8, is in preclinical development with IND submission planned for the second half of 2022[88]. - HBM9378, targeting TSLP, received IND approval in February 2022 and is set to initiate the I phase clinical trial in the second half of 2022[89]. - HBM1007 is a fully human monoclonal antibody targeting CD73, currently in preclinical research, with an IND application expected in the second half of 2022[90]. - HBM9033, an antibody-drug conjugate (ADC) targeting mesothelin, is also in preclinical research, with an IND application anticipated in 2023[93]. - HBM9027, a novel PD-L1xCD40 bispecific antibody, is in preclinical research, with an IND application expected in 2023[94]. Financial Performance - Revenue for the six months ended June 30, 2022, was $27.63 million, a significant increase from $2.21 million in the same period of 2021, representing a growth of approximately 1,150%[20]. - The company reported a net loss of $73.08 million for the first half of 2022, compared to a net loss of $61.62 million in the same period of 2021, indicating a deterioration of approximately 19%[20]. - Research and development expenses increased to $83.62 million in the first half of 2022, compared to $41.18 million in the same period of 2021, reflecting a rise of about 103%[20]. - The gross profit for the same period was $27.56 million, compared to $2.21 million in 2021, indicating a substantial improvement in profitability[197]. - The company incurred a loss before tax of $72.85 million, compared to a loss of $61.60 million in the previous year, reflecting an increase in losses of approximately 18%[197]. - Total administrative expenses decreased to $15.34 million from $25.27 million year-on-year, showing a reduction of about 39%[197]. - The total loss for the half-year ended June 30, 2022, was $73.1 million, an increase of $11.5 million from the loss of $61.6 million for the half-year ended June 30, 2021[123]. Collaborations and Partnerships - In 2022, the company entered a global licensing agreement with AstraZeneca for HBM7022, a bispecific antibody developed from its HBICE® platform[11]. - The company has established over 50 collaborations with industry and academic partners to maximize the value of its antibody platforms[11]. - The company is advancing strategic collaborations for innovative monoclonal antibodies and bispecific antibody drugs, aiming to submit IND applications in 2022 and 2023[23]. - The company has established a collaboration project with LegoChem Biosciences Inc. and Ying En Biotechnology Co., focusing on antibody-drug conjugates (ADC) for monoclonal antibodies, which includes upfront payments, milestone payments, and royalties based on sales[52]. - The strategic collaboration with Hualan Gene Engineering Co. aims to submit IND applications for three innovative monoclonal antibodies and bispecific antibody drugs (HBM1029, HBM7015, HBM7020) in 2022 and 2023[55]. - The partnership with Baidu Biotechnology has been deepened to develop innovative therapies combining the Harbour Mice® platform and AI technology, enhancing the discovery and preclinical development processes[56]. - The company has received milestone payments from its collaboration with Innovent Biologics, with additional payments expected in the second half of 2022 due to multiple clinical studies initiated[57]. - The collaboration with Boston Children's Hospital has made significant progress with the core candidate drug HBM9013, planning to submit an IND application in the U.S. in 2023[58]. Research and Development Strategy - The company aims to develop highly differentiated products that meet clinical needs, leveraging its proprietary antibody technology platform[47]. - The company is focusing on expanding its HCAb platform into new application areas, including CAR-T, CAR-NK, ADC, and nucleic acid collaborations[11]. - The company is actively expanding collaborations with leading academic institutions and industry partners to maximize platform value[49]. - The company is exploring NK cell therapies through a non-exclusive licensing agreement with Enkasei Pharma[51]. - The company has established a robust antibody discovery platform, including Harbour Mice® and HBICE® platforms, to advance towards novel and challenging drug targets[97]. - The company plans to accelerate the advancement of its product pipeline, including multiple clinical trials for core products Bartolizumab and Tenalisumab[109]. - The company anticipates submitting at least two new products for IND approval in the near future[109]. Corporate Governance and Compliance - The company has adopted the new corporate governance code effective from January 1, 2022, and has established its own governance policies to comply with the updated standards[142]. - The board believes that having the same person serve as both chairman and CEO ensures consistent internal leadership and effective strategic planning[143]. - The audit committee has reviewed the unaudited interim results for the six months ended June 30, 2022, ensuring the adequacy and effectiveness of the financial reporting system[148]. - The company has established a nomination committee and a remuneration committee in addition to the audit committee[149]. Market and Industry Context - The Chinese healthcare reform continues to deepen, presenting both challenges and opportunities for the pharmaceutical industry[46]. - The company’s pipeline products are expected to have broad market prospects due to ongoing industry demand and innovation[47]. Intellectual Property - The company applied for 47 patents during the reporting period, with 9 granted and 152 pending, enhancing intellectual property protection for core products and technology platforms[96].

HARBOUR BIOMED 和 鉗 醫 藥 控 股 有 限 公 司 HBM HOLDINGS LIMITED （於開曼群島註冊成立的有限公司） 股份代號 : 02142 2021 年 度 報 告 公司資料 2 公司概況 4 財務摘要 6 業務摘要 7 主席致辭 11 管理層討論與分析 14 董事及高級管理層 33 董事會報告 39 企業管治報告 64 風險管理報告 81 獨立核數師報告 83 綜合損益表 88 綜合全面收益表 89 綜合財務狀況表 90 綜合權益變動表 92 綜合現金流量表 94 綜合財務報表附註 97 釋義 177 目錄 和鉑醫藥控股有限公司 年報2021 公司資料 | --- | --- | |-----------------------------------|----------------------------------------------------------------------------| | | | | 董事會 | 聯席公司秘書 | | 執行董事 | 傅裕先生 | | 王勁松博士 （首席執行官）（主席） | 呂穎一先生 | | 陳小祥先生 | 開曼群島註冊辦 ...

HARBOUR BIOMED 和 鉑 醫 藥 控 股 有 限 公 司 HBM HOLDINGS LIMITED （於開曼群島註冊成立的有限公司） 股份代號：02142 2021 中 報 | --- | --- | --- | --- | --- | |-------|-------|-------|-------------------------------------------------------------------------------------------------------------------------------------|-------------------| | | | | | | | | | | | | | | | | | | | | | | | 目錄 | | | | | | | | | | | 公司資料 | 2 | | | | | 公司概況 | 3 | | | | | 財務摘要 | 5 | | | | | 業務摘要 | 6 | | | | | 管理層討論與分析 | 8 | | | | | | | | | | | 企業管治╱其他資料 | 26 | | | | | ...

和鉑醫藥控股有限公司 HBM HOLDINGS LIMITED （於開曼群島註冊成立的有限公司） 股份代號 : 02142 年報 2020 目錄 公司資料 2 公司概況 3 財務摘要 5 業務摘要 6 主席致辭 8 管理層討論與分析 11 董事及高級管理層 28 董事會報告 34 企業管治報告 60 獨立核數師報告 74 綜合損益表 80 綜合全面收益表 81 綜合財務狀況表 82 綜合權益變動表 84 綜合現金流量表 86 綜合財務報表附註 88 釋義 165 和鉑醫藥控股有限公司 年報2020 公司資料 | --- | --- | |------------------------------------------------------------|--------------------------------------------------------------------------------| | | | | 董事會 | 中國主要營業地 | | 執行董事 | 中國上海市 | | 王勁松博士 廖邁菁博士 | 徐匯區楓林路 420 號 楓林國際大廈二期 A 座 12 樓 | | Atul ...